acute%20coronary%20syndromes%20w_out%20persistent%20st-segment%20elevation
ACUTE CORONARY SYNDROMES W/OUT PERSISTENT ST-SEGMENT ELEVATION
Acute coronary syndromes refer to any constellation of clinical symptoms compatible with acute myocardial ischemia which may be life-threatening.
It encompasses unstable angina, non-ST-segment elevation myocardial infarction (NSTEMI) and ST-segment elevation myocardial infarction (STEMI).
Unstable angina is the ischemic discomfort that presents without persistent ST-segment elevation on ECG and without the presence of cardiac markers in the blood.
Non-ST-segment elevation myocardial infarction is diagnosed if cardiac markers are positive with ST-segment depression or with nonspecific or normal ECGs.
The patient typically presents with ischemic-type chest pain that is severe and prolonged and may occur at rest or may be caused by less exertion than previous episodes.

Supportive Therapy

Bed Rest

  • Usually prescribed initially in patients with UA/NSTEMI while ischemia is ongoing
    • Patient can be mobilized to bedside commode or chair when symptom-free
  • Ambulation as tolerated may begin once patient has been hemodynamically stable without recurrent symptoms for 12-24 hours
    • Subsequent activity should not be inappropriately restricted
    • Focus should be on the prevention of recurrent symptoms and activity may be increased once patient responds to therapy

Supplemental O2

  • Give supplemental O2 to all patients with overt pulmonary congestion or arterial O2 saturation <90% or respiratory distress or other high-risk features of hypoxemia
  • Consider in all patients with ACS for the 1st 6 hours of therapy
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Christina Lau, 06 Sep 2017

In patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI), dual antithrombotic therapy with dabigatran and a P2Y12 inhibitor significantly reduces bleeding vs triple therapy with warfarin, a P2Y12 inhibitor and aspirin, with comparable rates of thromboembolic events, results of the RE-DUAL PCI trial have shown.

6 days ago
Slideshow: Highlights from the Asian Pacific Society of Cardiology 2019 Congress
20 hours ago
A study has recently derived and validated a new index for preoperative cardiovascular evaluation, which can significantly contribute to the efficient triage and management of patients scheduled for noncardiac surgery. The new Cardiovascular Risk Index (CVRI) demonstrates a robust discriminatory power that can effectively stratify patients into low-, intermediate- and high-risk groups.
04 Jun 2019
The addition of alirocumab to intensive statin therapy appears to cut the risk of death following acute coronary syndrome, especially if treatment is sustained for at least 3 years, if baseline low-density lipoprotein cholesterol (LDL-C) is ≥100 mg/dL or if achieved LDL-C is low, according to data from the ODYSSEY OUTCOMES.